SOST and breast carcinoma: Sclerostin was increased in the breast cancer metastatic cell line, MDA-MB 231, and in the nonmetastatic cell line, MCF-7, due to the abnormal overexpression of Runx2, which binds to the proximal promoter of the SOST gene.